Apellis Pharmaceuticals Inc. (APLS)
Market Closed
15 May, 20:00
$
41. 03
0
0%
$
5.25B Market Cap
- P/E Ratio
- Div Yield
28.64M Volume
-4.51 Eps
$ 41.03
Previous Close Investors:
Want to track APLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Zacks | 1 year ago
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Zacks | 1 year ago
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
Zacks | 2 years ago
